Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International's Operating Expenses history runs 10 years deep, the most recent figure standing at $185.0 million for Q1 2026.

• Quarterly Operating Expenses rose 48.58% year-over-year to $185.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $660.8 million (up 32.97% YoY) and the FY2025 annual result came in at $600.3 million, up 28.04% from the prior year.
• Operating Expenses was $185.0 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $182.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $185.0 million in Q1 2026 and bottomed at $46.3 million in Q2 2022.
• A 5-year average of $103.5 million and a median of $96.4 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses dropped 3.98% — and 2024, when it jumped 70.24%.
• Kiniksa Pharmaceuticals International's Operating Expenses stood at $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then jumped by 70.24% to $141.8 million in 2024, then advanced by 28.57% to $182.4 million in 2025, then rose by 1.45% to $185.0 million in 2026.
• Business Quant data shows KNSA's Operating Expenses at $185.0 million in Q1 2026, $182.4 million in Q4 2025, and $156.8 million in Q3 2025.